(058) Does Ecstasy Have Treatment Potential in Female Sexual Dysfunction? A Systematic Review of Effects on the Female Sexual Response Cycle

Abstract Introduction Female sexual dysfunction (FSD) is a highly prevalent and distressing condition, yet limited treatment modalities have been established incorporated into clinical practice to address this condition. 3,4-Methylenedioxy-methamphetamine (MDMA, ‘Ecstasy’ or ‘Molly’) psychostimulant affecting central serotonin, dopamine, norepinephrine neurotransmission. These same neurotransmitters play important roles in function which suggests that MDMA has potential be utilized as novel strategy for FSD. Objective The purpose of systematic review evaluate effects on different domains female response cycle. Methods We conducted the various PubMed, MEDLINE, EMBASE were queried, results screened using Preferred Reporting Items Systematic Reviews Meta-Analyses (PRISMA) guidelines. Search terms, including “MDMA” “ecstasy” combination with “desire,” “arousal”, “lubrication”, “orgasm”, “pleasure”, “libido,” utilized. Inclusion criteria were: was used by study subjects, outcomes at least one domain cycle described measured, manuscript written English between January 2000 June 2022. Case reports studies did not conditions interest excluded from analysis. Results identified total 175 studies. Of these, six 155 women met our inclusion exclusion criteria. Four studies, randomized control study, reported increased desire use. Arousal lubrication improved three four but affected based study. Orgasm after delayed difficult reach, more intense pleasurable if achieved. Conclusions This demonstrates need further investigation effect While orgasm certain available data, there conflicting evidence about enhancing arousal. illicit unregulated recreational drug, findings should interpreted caution. Disclosure Any authors act consultant, employee shareholder an industry for: Abbvie, Coloplast, Sprout Pharmaceuticals.